Sugi Predict

Sugi Predict / Compounds / SCHEMBL25315913

SCHEMBL25315913

SCHEMBL25315913

CC(C)(C)OC(=O)N1CCC2(CC1)C(=O)N(COCC[Si](C)(C)C)c1ccc(O)cc12

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ ESR2 Q92731 1/20 0.39
▸ TACR1 P25103 1/20 0.38
▸ NAMPT P43490 5/20 0.37
▸ OPRD1 P41143 1/20 0.36
▸ OPRK1 P41145 1/20 0.36
▸ PKM P14618 1/20 0.35
▸ JAK2 O60674 1/20 0.35
▸ JAK1 P23458 1/20 0.35
▸ SMARCA2 P51531 1/20 0.34
▸ SMARCA4 P51532 1/20 0.34
▸ PBRM1 Q86U86 1/20 0.34
▸ HRH3 Q9Y5N1 2/20 0.34
▸ GPR119 Q8TDV5 1/20 0.34
▸ BACE1 P56817 1/20 0.34
▸ KDM1A O60341 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30506821 1.00 ESR2 (0.39) ESR2TACR1NAMPTOPRD1OPRK1
SCHEMBL31436447 0.90 DDR1 (0.41) NAMPTOPRD1OPRK1JAK2JAK1
SCHEMBL30506793 0.90 DDR1 (0.41) TACR1NAMPTPKMJAK2JAK1
SCHEMBL25317620 0.90 DDR1 (0.41) TACR1NAMPTPKMJAK2JAK1
SCHEMBL25316481 0.88 OPRL1 (0.36) OPRD1OPRK1
SCHEMBL25317240 0.87 TACR1 (0.35) TACR1NAMPTOPRD1OPRK1HRH3
SCHEMBL30507038 0.87 TACR1 (0.35) TACR1NAMPTOPRD1OPRK1HRH3
SCHEMBL25315612 0.86 PRMT5 (0.42) TACR1NAMPTOPRD1OPRK1PKM
SCHEMBL15699763 0.79 NAMPT (0.37) NAMPTOPRD1OPRK1PKMGPR119
SCHEMBL20955524 0.79 IP6K1 (0.48) ESR2TACR1OPRD1OPRK1SMARCA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2025-09-11 — — US disclosed
US-12344610-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2025-07-01 — — US disclosed
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-12-05 — — US disclosed
US-11976067-B2 APOL1 inhibitors and methods of use MAZE THERAPEUTICS, INC. (US) 2024-05-07 — — US disclosed
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2023-08-24 — — US disclosed
WO-2023141432-A2 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2023-07-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265096-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, LDLR ESR2 1537/4885TACR1 2658/4885NAMPT 2478/4885
US-12344610-B2 APOL1 inhibitors and methods of use APOL1, APOB, PON1 ESR2 1445/4885TACR1 2608/4885NAMPT 2288/4885
US-11976067-B2 APOL1 inhibitors and methods of use APOL1, APOB, LDLR ESR2 1537/4885TACR1 2658/4885NAMPT 2478/4885
US-20250282781-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ESR2 1445/4885TACR1 2608/4885NAMPT 2288/4885
US-20240400565-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, APOB, PON1 ESR2 1445/4885TACR1 2608/4885NAMPT 2288/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.